Somatic Comorbidities and Cardiovascular Safety in Ketamine Use for Treatment-Resistant Depression

被引:11
作者
Szarmach, Joanna [1 ]
Cubala, Wieslaw Jerzy [1 ]
Wlodarczyk, Adam [1 ]
Galuszko-Wegielnik, Maria [1 ]
机构
[1] Med Univ Gdansk, Fac Med, Dept Psychiat, 7 Debinki St,Build 25, PL-80952 Gdansk, Poland
来源
MEDICINA-LITHUANIA | 2021年 / 57卷 / 03期
关键词
ketamine; treatment-resistant depression; cardiac safety; blood pressure; safety; tolerability; ANTIDEPRESSANT; PAIN;
D O I
10.3390/medicina57030274
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives: There is evidence for ketamine efficacy in treatment-resistant depression (TRD). Several safety and tolerability concerns arise that some psychotropic agents may provide blood pressure or/and heart rate alterations. The aim of this study is to review blood pressure measurements in course of the treatment with ketamine on treatment refractory inpatients with somatic comorbidities in the course of MDD and BP. Materials and Methods: The study population of 49 patients comprised MDD and BP subjects treated with ketamine registered in the naturalistic observational protocol of treatment-resistant mood disorders (NCT04226963). Results: The conducted analysis showed that among people suffering from hypertension there is a higher increase in systolic blood pressure (RR) after infusion 2 (p = 0.004) than among people who do not suffer from hypertension. Patients with hypertension have a higher increase in diastolic RR compared to those not suffering from hypertension (p = 0,038). Among the subjects with diabetes mellitus, significant differences occurred for infusions 2 (p = 0.020), 7 (p = 0.020), and 8 (p = 0.035) for heart rate (HR), compared to subjects without diabetes mellitus. A higher increase in diastolic RR was noted in the group of subjects suffering from diabetes mellitus (p = 0.010) compared to those who did not. In the hyperlipidemic patients studied, a significantly greater decrease in HR after infusion 5 (p = 0.031) and systolic RR after infusion 4 (p = 0.036) was noted compared to nonpatients. People after a stroke had significantly higher increases in diastolic RR after infusions 4 (p = 0.021) and 6 (p = 0.001) than those who did not have a stroke. Patients suffering from epilepsy had a significantly greater decrease in systolic RR after the 8th infusion (p = 0.017) compared to those without epilepsy. Limitations: The study may be underpowered due to the small sample size. The observations apply to inhomogeneous TRD population in a single-site with no blinding and are limited to the acute administration. Conclusions: This study supports evidence for good safety and tolerability profile for short-term IV ketamine use in TRD treatment. However, risk mitigation measures are to be considered in patients with metabolic and cardiovascular comorbidities.
引用
收藏
页数:8
相关论文
共 50 条
[41]   Plasma inflammatory cytokines and treatment-resistant depression with comorbid pain: improvement by ketamine [J].
Zhou, Yanling ;
Wang, Chengyu ;
Lan, Xiaofeng ;
Li, Hanqiu ;
Chao, Ziyuan ;
Ning, Yuping .
JOURNAL OF NEUROINFLAMMATION, 2021, 18 (01)
[42]   Safety outcomes of ketamine for treatment-resistant depression in clinical settings and development of the ketamine side effect tool-revised (KSET-R) [J].
Bayes, Adam ;
Cao, Thanh Vinh ;
Barreiros, Ana Rita ;
Massaneda-Tuneu, Clara ;
Dong, Vanessa ;
Thornton, Nicollette ;
Glozier, Nicholas ;
Beesley, Laura ;
Moreno, Dalia ;
Galvez-Ortiz, Veronica ;
Short, Brooke ;
Martin, Donel ;
Loo, Colleen .
PSYCHIATRY RESEARCH, 2025, 344
[43]   Anhedonia and depression severity measures during ketamine administration in treatment-resistant depression [J].
Kwasny, Aleksander ;
Cubala, Wieslaw Jerzy ;
Wlodarczyk, Adam .
FRONTIERS IN PSYCHIATRY, 2024, 15
[44]   Use of Staging Models for Treatment-Resistant Depression Is Not Helpful in Predicting Nonresponse to Acute Intravenous Ketamine Treatment [J].
Sakurai, Hitoshi ;
Hoeppner, Bettina ;
Jain, Felipe ;
Foster, Simmie ;
Pedrelli, Paola ;
Mischoulon, David ;
Fava, Maurizio ;
Cusin, Cristina .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2022, 42 (02) :140-145
[45]   Off-label use of ketamine for treatment-resistant depression in clinical practice: European perspective [J].
Lopez-Diaz, Alvaro ;
Murillo-Izquierdo, Manuel ;
Moreno-Mellado, Elisa .
BRITISH JOURNAL OF PSYCHIATRY, 2019, 215 (02) :447-448
[46]   Copper Concentrations in Ketamine Therapy for Treatment-Resistant Depression [J].
Slupski, Jakub ;
Cubala, Wieslaw Jerzy ;
Gorska, Natalia ;
Slupska, Anita ;
Galuszko-Wegielnik, Maria .
BRAIN SCIENCES, 2020, 10 (12) :1-9
[47]   Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression [J].
Acevedo-Diaz, Elia E. ;
Cavanaugh, Grace W. ;
Greenstein, Dede ;
Kraus, Christoph ;
Kadriu, Bashkim ;
Zarate, Carlos A. ;
Park, Lawrence T. .
JOURNAL OF AFFECTIVE DISORDERS, 2020, 263 :568-575
[48]   Ketamine for Treatment-Resistant Depression A Gateway to Novel Treatment Approaches [J].
Limandri, Barbara J. .
JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES, 2018, 56 (10) :11-14
[49]   A Systematic Review on Ketamine and Esketamine for Treatment-Resistant Depression and Suicidality in Adolescents: A New Hope? [J].
Pardossi, Simone ;
Fagiolini, Andrea ;
Scheggi, Simona ;
Cuomo, Alessandro .
CHILDREN-BASEL, 2024, 11 (07)
[50]   Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report [J].
Joseph, Boney ;
Nunez, Nicolas A. ;
Kung, Simon ;
Voort, Jennifer L. Vande ;
Pazdernik, Vanessa K. ;
Schak, Kathryn M. ;
Boehm, Stacey M. ;
Carpenter, Brooke ;
Johnson, Emily K. ;
Malyshev, Grigoriy ;
Smits, Nathan ;
Adewunmi, Daniel O. ;
Brown, Sarah K. ;
Singh, Balwinder .
PHARMACEUTICALS, 2023, 16 (08)